The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. Th...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3871531?pdf=render |
id |
doaj-e562921b6e994148966ffc9a7ab695c4 |
---|---|
record_format |
Article |
spelling |
doaj-e562921b6e994148966ffc9a7ab695c42020-11-24T20:49:54ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8383010.1371/journal.pone.0083830The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.Stefania FiorcariWells S BrownBradley W McIntyreZeev EstrovRossana MaffeiSusan O'BrienMariela SivinaJulia HoellenriegelWilliam G WierdaMichael J KeatingWei DingNeil E KayBrian J LannuttiRoberto MarascaJan A BurgerCLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. This characteristic activity presumably is due to CLL cell redistribution from tissues into the blood, but the underlying mechanisms are not fully understood. We therefore analyzed idelalisib effects on CLL cell adhesion to endothelial and bone marrow stromal cells (EC, BMSC). We found that idelalisib inhibited CLL cell adhesion to EC and BMSC under static and shear flow conditions. TNFα-induced VCAM-1 (CD106) expression in supporting layers increased CLL cell adhesion and accentuated the inhibitory effect of idelalisib. Co-culture with EC and BMSC also protected CLL from undergoing apoptosis, and this EC- and BMSC-mediated protection was antagonized by idelalisib. Furthermore, we demonstrate that CLL cell adhesion to EC and VLA-4 (CD49d) resulted in the phosphorylation of Akt, which was sensitive to inhibition by idelalisib. These findings demonstrate that idelalisib interferes with integrin-mediated CLL cell adhesion to EC and BMSC, providing a novel mechanism to explain idelalisib-induced redistribution of CLL cells from tissues into the blood.http://europepmc.org/articles/PMC3871531?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Stefania Fiorcari Wells S Brown Bradley W McIntyre Zeev Estrov Rossana Maffei Susan O'Brien Mariela Sivina Julia Hoellenriegel William G Wierda Michael J Keating Wei Ding Neil E Kay Brian J Lannutti Roberto Marasca Jan A Burger |
spellingShingle |
Stefania Fiorcari Wells S Brown Bradley W McIntyre Zeev Estrov Rossana Maffei Susan O'Brien Mariela Sivina Julia Hoellenriegel William G Wierda Michael J Keating Wei Ding Neil E Kay Brian J Lannutti Roberto Marasca Jan A Burger The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS ONE |
author_facet |
Stefania Fiorcari Wells S Brown Bradley W McIntyre Zeev Estrov Rossana Maffei Susan O'Brien Mariela Sivina Julia Hoellenriegel William G Wierda Michael J Keating Wei Ding Neil E Kay Brian J Lannutti Roberto Marasca Jan A Burger |
author_sort |
Stefania Fiorcari |
title |
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. |
title_short |
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. |
title_full |
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. |
title_fullStr |
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. |
title_full_unstemmed |
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. |
title_sort |
pi3-kinase delta inhibitor idelalisib (gs-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (cll) cell to endothelial and marrow stromal cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
CLL cell trafficking between blood and tissue compartments is an integral part of the disease process. Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor causes rapid lymph node shrinkage, along with an increase in lymphocytosis, prior to inducing objective responses in CLL patients. This characteristic activity presumably is due to CLL cell redistribution from tissues into the blood, but the underlying mechanisms are not fully understood. We therefore analyzed idelalisib effects on CLL cell adhesion to endothelial and bone marrow stromal cells (EC, BMSC). We found that idelalisib inhibited CLL cell adhesion to EC and BMSC under static and shear flow conditions. TNFα-induced VCAM-1 (CD106) expression in supporting layers increased CLL cell adhesion and accentuated the inhibitory effect of idelalisib. Co-culture with EC and BMSC also protected CLL from undergoing apoptosis, and this EC- and BMSC-mediated protection was antagonized by idelalisib. Furthermore, we demonstrate that CLL cell adhesion to EC and VLA-4 (CD49d) resulted in the phosphorylation of Akt, which was sensitive to inhibition by idelalisib. These findings demonstrate that idelalisib interferes with integrin-mediated CLL cell adhesion to EC and BMSC, providing a novel mechanism to explain idelalisib-induced redistribution of CLL cells from tissues into the blood. |
url |
http://europepmc.org/articles/PMC3871531?pdf=render |
work_keys_str_mv |
AT stefaniafiorcari thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT wellssbrown thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT bradleywmcintyre thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT zeevestrov thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT rossanamaffei thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT susanobrien thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT marielasivina thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT juliahoellenriegel thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT williamgwierda thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT michaeljkeating thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT weiding thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT neilekay thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT brianjlannutti thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT robertomarasca thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT janaburger thepi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT stefaniafiorcari pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT wellssbrown pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT bradleywmcintyre pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT zeevestrov pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT rossanamaffei pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT susanobrien pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT marielasivina pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT juliahoellenriegel pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT williamgwierda pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT michaeljkeating pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT weiding pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT neilekay pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT brianjlannutti pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT robertomarasca pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells AT janaburger pi3kinasedeltainhibitoridelalisibgs1101targetsintegrinmediatedadhesionofchroniclymphocyticleukemiacllcelltoendothelialandmarrowstromalcells |
_version_ |
1716805529945243648 |